Novo Nordisk and Eli Lilly cracked the code on weight-loss pills. GLP-1 drugs in pill form mean no more needles. Just swallow and watch the pounds melt off. Consumer demand will explode because Americans love pills more than they love their own children.
Employer-sponsored health insurance plans have already started running the numbers. The numbers are bad. Really bad. Covering weight-loss drugs for an entire workforce costs more than just letting Doug from accounting stay fat. Doug makes sixty grand a year and eats his feelings in the break room. His annual premium contribution is four thousand dollars. A year of GLP-1 pills runs north of twelve thousand dollars. The math does not math.
Insurance companies will exclude coverage. They will cite the technical definition of cosmetic versus medical necessity. They will lose exactly zero sleep over it. Employers will nod along because they already cut the dental plan to bronze tier. Workers will pay out of pocket or stay heavy. Most will stay heavy because twelve grand buys a used Camry with hail damage.
This is fantastic news for the med-device companies selling the injectable versions under patent protection. Pill form was supposed to democratize access. Instead it democratized disappointment. The injectables stay expensive. The pills stay expensive. The only thing that got cheaper was the excuse employers give for not covering either one.
Retail traders heard GLP-1 pill and bought Novo Nordisk calls with money they should have spent on a gym membership. They will lose both the premium and the weight argument when their insurance sends them a polite letter explaining that being fat is a pre-existing condition they should have thought about before being born.
Doug still eats lunch in his car.
Photo by on Unsplash
Leave a Comment